What is Retatrutide? A plain-English explainer
An investigational peptide designed to act on three metabolic hormone receptors at once; it has not been approved as a medicine.
Retatrutide is an investigational peptide drug candidate engineered to act on three separate metabolic hormone receptors — GLP-1, GIP, and glucagon — in a single molecule. It is still in clinical trials and has not been approved by the FDA or any other regulatory agency for any use. It is sold and handled as a research compound while those trials continue, not as a medicine.
That’s the whole definition in one paragraph. The rest of this page unpacks it at two levels — plain English, then a little deeper — and explains how the reconstitution math works, because retatrutide, like most research peptides, typically ships as a dried powder that has to be mixed and measured before anything else.
Retatrutide in plain English
Retatrutide is a peptide — a chain of amino acids — but a comparatively large one, built from around 39 residues with a fatty-acid chain attached to help it stay active in the body longer.
The part that makes retatrutide unusual is what it’s designed to fit. Hormone receptors act like docking stations — a receptor and its matching hormone fit together like a lock and key. Most peptides in this drug class are built to fit one lock (the GLP-1 receptor). Retatrutide was engineered to fit three: the GLP-1, GIP, and glucagon receptors. That’s what “triple agonist” means — three locks, one key.
It’s still an investigational molecule. That word matters: it means retatrutide is a candidate being tested in clinical trials to see whether it is safe and effective enough to become an approved drug — a question that has not yet been answered by any regulator. Until it is, retatrutide is not a medicine you can be prescribed.
The science, a little deeper
A few specifics the plain-English version simplifies:
- It’s a defined, engineered sequence. Retatrutide (laboratory code LY3437943) is roughly 39 amino acids long, built on a GIP-receptor-agonist backbone that was then modified so it also binds and activates the GLP-1 and glucagon receptors.
- A fatty-acid chain extends its activity. A lipid (fatty-acid) side chain is attached to the peptide backbone, which is a common design technique in this drug class used to slow clearance from the body.
- “Investigational” is a regulatory category, not a marketing word. Retatrutide is currently in Phase 3 clinical trials — the stage that precedes a regulatory filing — sponsored by Eli Lilly, studying it in people with obesity and type 2 diabetes. A completed trial program and a regulatory review would both have to happen before any approval could occur, and none has occurred yet.
- This page makes no claim about what it does for a person. Clinical trials exist specifically to answer that question, and the answer isn’t settled by an approval yet.
If you want the classification in one line: retatrutide is an investigational triple-agonist peptide, roughly 39 amino acids with a fatty-acid modification, currently in Phase 3 trials and not an approved drug.
How reconstitution works for Retatrutide
Reconstitution is the process of dissolving a lyophilised (freeze-dried) peptide powder in a known volume of liquid so you have a concentration — milligrams of peptide per millilitre of solution. Once the concentration is fixed, the volume to draw for any target amount is simple arithmetic:
- Concentration = vial amount (mg) ÷ diluent volume (mL)
- Draw volume = target amount ÷ concentration
- Syringe units = draw volume (mL) × the units-per-mL of your syringe
All three numbers come from your own vial label and your own paperwork — the peptide amount printed on the vial, the volume of diluent you add, and the target amount you were told to use. The separate Amidra web calculator runs exactly those three steps and shows the formula at each one, so you can check it by hand. It never fills in a number for you.
What Amidra does — and doesn’t — do here
Amidra is a tracking and education tool. It converts the values you enter and helps keep a research or clinical-trial protocol organised; it does not recommend a dose, a compound, or a schedule, and it takes no position on retatrutide’s regulatory future or on whether anyone should use it. Those decisions belong with a qualified healthcare professional or clinical trial investigator. The information above is definitional — what the compound is and where it stands regulatory-wise — not medical advice.